TGFβ Signaling and Cardiovascular Diseases

被引：2

作者：

Pardali, Evangelia ^{[1
]}

ten Dijke, Peter ^{[2
,3
]}

机构：

[1] Univ Hosp Munster, Dept Cardiol & Angiol, Munster, Germany

[2] Leiden Univ, Med Ctr, Ctr Biomed Genet, Leiden, Netherlands

[3] Leiden Univ, Med Ctr, Dept Mol Cell Biol, Leiden, Netherlands

来源：

INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES | 2012年 / 8卷 / 02期

关键词：

atherosclerosis; BMP; hypertension; Smad; TGF beta; vessel calcification; TRANSFORMING-GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; BONE MORPHOGENETIC PROTEIN; HEREDITARY HEMORRHAGIC TELANGIECTASIA; PULMONARY ARTERIAL-HYPERTENSION; NITRIC-OXIDE SYNTHASE; HUMAN ATHEROSCLEROTIC LESIONS; VASCULAR ENDOTHELIAL-CELLS; AORTIC-ANEURYSM PROGRESSION; RECEPTOR-LIKE KINASE-1;

D O I：

10.7150/ijbs.8.195

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Transforming growth factor beta (TGF beta) family members are involved in a wide range of diverse functions and play key roles in embryogenesis, development and tissue homeostasis. Perturbation of TGF beta signaling may lead to vascular and other diseases. In vitro studies have provided evidence that TGF beta family members have a wide range of diverse effects on vascular cells, which are highly dependent on cellular context. Consistent with these observations genetic studies in mice and humans showed that TGF beta family members have ambiguous effects on the function of the cardiovascular system. In this review we discuss the recent advances on TGF beta signaling in (cardio) vascular diseases, and describe the value of TGF beta signaling as both a disease marker and therapeutic target for (cardio) vascular diseases.

引用

页码：195 / 213

页数：19

共 50 条

[31] Inhibition of TGF-β Signaling for the Treatment of Tumor Metastasis and Fibrotic Diseases
Fuchs, Ota
CURRENT SIGNAL TRANSDUCTION THERAPY, 2011, 6 (01) : 29 - 43
[32] Integrin function and signaling as pharmacological targets in cardiovascular diseases and in cancer
Paulhe, F
Manenti, S
Ysebaert, L
Betous, R
Sultan, P
Racaud-Sultan, C
CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (16) : 2119 - 2134
[33] The Positive Regulation of eNOS Signaling by PPAR Agonists in Cardiovascular Diseases
Cristina Maccallini
Adriano Mollica
Rosa Amoroso
American Journal of Cardiovascular Drugs, 2017, 17 : 273 - 281
[34] Signaling Pathways in Inflammation and Cardiovascular Diseases: An Update of Therapeutic Strategies
Cucu, Ioana
IMMUNO, 2022, 2 (04): : 630 - 650
[35] Estrogen signaling as a bridge between the nucleus and mitochondria in cardiovascular diseases
Guajardo-Correa, Emanuel
Francisco Silva-Aguero, Juan
Calle, Ximena
Chiong, Mario
Henriquez, Mauricio
Garcia-Rivas, Gerardo
Latorre, Mauricio
Parra, Valentina
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 10
[36] How Hippo Signaling Pathway Modulates Cardiovascular Development and Diseases
Zhou, Wenyi
Zhao, Mingyi
JOURNAL OF IMMUNOLOGY RESEARCH, 2018, 2018
[37] Regulatory effects of resveratrol on nitric oxide signaling in cardiovascular diseases
Abolfazli, Sajad
Karav, Sercan
Johnston, Thomas P.
Sahebkar, Amirhossein
PHARMACOLOGICAL REPORTS, 2025, 77 (02) : 355 - 374
[38] INNATE IMMUNE SIGNALING AND ITS ROLE IN METABOLIC AND CARDIOVASCULAR DISEASES
Xu, Meng
Liu, Peter P.
Li, Hongliang
PHYSIOLOGICAL REVIEWS, 2019, 99 (01) : 893 - 948
[39] Cardioproteomics: advancing the discovery of signaling mechanisms involved in cardiovascular diseases
Cui, Ziyou
Dewey, Shannamar
Gomes, Aldrin V.
AMERICAN JOURNAL OF CARDIOVASCULAR DISEASE, 2011, 1 (03): : 274 - 292
[40] The Positive Regulation of eNOS Signaling by PPAR Agonists in Cardiovascular Diseases
Maccallini, Cristina
Mollica, Adriano
Amoroso, Rosa
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2017, 17 (04) : 273 - 281

← 1 2 3 4 5 →